MacroGenics Provides Update on Corporate Progress and 2024 Financial Results Fully enrolled LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPCInitiating new LINNET Phase 2 study of lorigerlimab in ovarian cancerAdvancing multiple novel topoisomerase 1 inhibitor-based ADCs, including MGC026, MGC028 and MGC030Discontinuing further internal clinical development of vobra duo; exploring potential partneringCash, cash equivalents and marketable securities of $201.7 million as of December 31, 2024; cash runway extended into the sec...
MacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference Call ROCKVILLE, MD, March 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the fourth quarter and full year of 2024 after the market closes on Thursday, March 20, 2025. MacroGenics will host a conference call to discuss the financial results and recent...
MacroGenics to Participate in Upcoming Investor Conferences ROCKVILLE, MD, Feb. 27, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences in March: TD Cowen 45th Annual Healthcare Conference (Boston). MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in a fireside chat on Wednesd...
FOSTER CITY, Calif.--(BUSINESS WIRE)-- QuinStreet, Inc. (Nasdaq: QNST), a leader in performance marketplaces and technologies for the financial services and home services industries, today announced that management will participate at Susquehanna's 14th Annual Technology Conference on February 27 in New York, NY. The Company looks forward to discussing the details of its performance momentum, market opportunity, and business model with investors. About QuinStreet QuinStreet, Inc. (Nasdaq: ) is a leader in performance marketplaces and technologies for the financial services and home services...
FOSTER CITY, Calif.--(BUSINESS WIRE)-- QuinStreet, Inc. (Nasdaq: QNST), a leader in performance marketplaces and technologies for the financial services and home services industries, today announced financial results for the fiscal second quarter ended December 31, 2024. For the fiscal second quarter, the Company reported revenue of $282.6 million, up 130% year-over-year. GAAP loss for the fiscal second quarter was $(1.5) million, or $(0.03) per diluted share. Adjusted net income for the fiscal second quarter was $11.9 million, or $0.20 per diluted share. Adjusted EBITDA for the fiscal s...
FOSTER CITY, Calif.--(BUSINESS WIRE)-- QuinStreet, Inc. (Nasdaq: QNST), a leader in performance marketplaces and technologies for the financial services and home services industries, today announced it will report financial results for its second quarter ended December 31, 2024 after the market closes on Thursday, February 6, 2025. On that day, management will hold a conference call and webcast at 2:00 PM PT to review and discuss the company’s results. What: QuinStreet Fiscal Second Quarter 2025 Financial Results Conference Call When: Thursday, February 6, 2025 ...
MacroGenics to Participate in Upcoming Investor Conference ROCKVILLE, MD, Dec. 02, 2024 (GLOBE NEWSWIRE) -- -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conference this month: 7th Annual Evercore HealthCONx (Coral Gables, FL). MacroGenics’ President and Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in a firesid...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
FOSTER CITY, Calif.--(BUSINESS WIRE)-- QuinStreet, Inc. (Nasdaq: QNST), a leader in performance marketplaces and technologies for the financial services and home services industries, today announced that management will participate at the Stephens Investment Conference from November 20-21 in Nashville, TN. The Company looks forward to discussing the details of its performance momentum, market opportunity, and business model with investors. About QuinStreet QuinStreet, Inc. (Nasdaq: ) is a leader in performance marketplaces and technologies for the financial services and home services ind...
MacroGenics to Participate in Upcoming Investor Conferences ROCKVILLE, MD, Nov. 06, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences this month: Guggenheim Securities Healthcare Innovation Conference (Boston). MacroGenics’ Chief Operating Officer, Eric Risser, will participate in a fireside chat on Tuesday, N...
MacroGenics Provides Update on Corporate Progress, Third Quarter 2024 Financial Results Strengthened financial position resulting from recently announced MARGENZA® transaction and previously announced receipt of milestone payment from Incyte related to advancement of ZYNYZ®ADAM9-directed ADC (MGC028) Investigational New Drug (IND) application submitted to FDA Conference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md., Nov. 05, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializi...
FOSTER CITY, Calif.--(BUSINESS WIRE)-- QuinStreet, Inc. (Nasdaq: QNST), a leader in performance marketplaces and technologies for the financial services and home services industries, today announced financial results for the fiscal first quarter ended September 30, 2024. For the fiscal first quarter, the Company reported revenue of $279.2 million, up 125% year-over-year. GAAP loss for the fiscal first quarter was $1.4 million, or $(0.02) per diluted share. Adjusted net income for the fiscal first quarter was $12.5 million, or $0.22 per diluted share. Adjusted EBITDA for the fiscal first qua...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.